Michael Davidson to Hypercholesterolemia
This is a "connection" page, showing publications Michael Davidson has written about Hypercholesterolemia.
Connection Strength
11.231
-
The Risk of Hepatotoxicity, New Onset Diabetes and Rhabdomyolysis in the Era of High-Intensity Statin Therapy: Does Statin Type Matter? Prog Cardiovasc Dis. 2016 Sep - Oct; 59(2):145-152.
Score: 0.459
-
Dyslipidaemia: PCSK9 antibodies: a dividend of the genomics revolution. Nat Rev Cardiol. 2013 Nov; 10(11):618-9.
Score: 0.376
-
Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2013 Dec 10; 62(23):2178-84.
Score: 0.375
-
A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia. Am J Cardiovasc Drugs. 2010; 10(5):305-14.
Score: 0.291
-
Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Curr Atheroscler Rep. 2009 Jan; 11(1):67-70.
Score: 0.271
-
Hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring in patients with a diagnosis of atherosclerosis in clinical practice. Am J Med. 2009 Jan; 122(1 Suppl):S51-9.
Score: 0.271
-
A review of lipid management in primary and secondary prevention. J Cardiopulm Rehabil Prev. 2009 Jan-Feb; 29(1):2-12.
Score: 0.271
-
Is it over for ezetimibe? Expert Rev Cardiovasc Ther. 2008 Jul; 6(6):781-3.
Score: 0.262
-
Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications. Cleve Clin J Med. 2008 Jul; 75(7):479-82, 486-8, 490-1.
Score: 0.262
-
High-dose statin therapy: benefits and safety in aggressive lipid lowering. J Fam Pract. 2008 May; 57(5 Suppl High-Dose):S29-36.
Score: 0.259
-
Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting. Am J Manag Care. 2007 Dec; 13 Suppl 10:S270-5.
Score: 0.252
-
Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database. Clin Ther. 2007 Nov; 29(11):2385-94.
Score: 0.250
-
Comparative effectiveness of rosuvastatin versus other statin therapies in patients at increased risk of failure to achieve low-density lipoprotein goals. Curr Med Res Opin. 2007 May; 23(5):1121-30.
Score: 0.242
-
Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2025 05 17; 405(10491):1757-1768.
Score: 0.211
-
Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract. 2004 Aug; 58(8):746-55.
Score: 0.200
-
Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups. Clin Cardiol. 2003 Nov; 26(11):509-14.
Score: 0.190
-
A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d. Clin Ther. 2003 Nov; 25(11):2738-53.
Score: 0.190
-
Efficacy of simvastatin and ezetimibe in treating hypercholesterolemia. J Am Coll Cardiol. 2003 Jul 16; 42(2):398-9; author reply 399.
Score: 0.186
-
Ezetimibe: a novel option for lowering cholesterol. Expert Rev Cardiovasc Ther. 2003 May; 1(1):11-21.
Score: 0.183
-
Food products containing free tall oil-based phytosterols and oat beta-glucan lower serum total and LDL cholesterol in hypercholesterolemic adults. J Nutr. 2003 Mar; 133(3):808-13.
Score: 0.181
-
Cholesterol-lowering drugs bring benefits to high-risk populations even when LDL is normal. J Cardiovasc Nurs. 2003 Jan-Mar; 18(1):44-9; quiz 75-6.
Score: 0.179
-
Lipid management and the elderly. Prev Cardiol. 2003; 6(3):128-33; quiz 134-5.
Score: 0.179
-
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002 Dec 18; 40(12):2125-34.
Score: 0.179
-
A symposium: National Cholesterol Education Program Adult Treatment Panel III: Impact and implementation of the new guidelines. Introduction. Am J Cardiol. 2002 Mar 07; 89(5A):1C-2C.
Score: 0.169
-
Strategies to improve Adult Treatment Panel III guideline adherence and patient compliance. Am J Cardiol. 2002 Mar 07; 89(5A):8C-20C; discussion 20C-22C.
Score: 0.169
-
Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol. 2002 Feb 01; 89(3):268-75.
Score: 0.168
-
A multiple-dose pharmacodynamic, safety, and pharmacokinetic comparison of extended- and immediate-release formulations of lovastatin. Clin Ther. 2002 Jan; 24(1):112-25.
Score: 0.167
-
Management of hypercholesterolaemia in postmenopausal women. Drugs Aging. 2002; 19(3):169-78.
Score: 0.167
-
Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc. 2001 Oct; 76(10):971-82.
Score: 0.164
-
Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol. 2001 Jun; 24(6):467-74.
Score: 0.160
-
Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med. 2001 Apr 01; 110(5):352-60.
Score: 0.159
-
Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. Drugs. 2001; 61(2):197-206.
Score: 0.156
-
Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia. Nutr Metab Cardiovasc Dis. 2000 Oct; 10(5):253-62.
Score: 0.153
-
Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med. 1999 Sep 13; 159(16):1893-900.
Score: 0.142
-
Effects of dietary inulin on serum lipids. J Nutr. 1999 07; 129(7 Suppl):1474S-7S.
Score: 0.140
-
Comparison of the effects of lean red meat vs lean white meat on serum lipid levels among free-living persons with hypercholesterolemia: a long-term, randomized clinical trial. Arch Intern Med. 1999 Jun 28; 159(12):1331-8.
Score: 0.140
-
A low-viscosity soluble-fiber fruit juice supplement fails to lower cholesterol in hypercholesterolemic men and women. J Nutr. 1998 Nov; 128(11):1927-32.
Score: 0.134
-
Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. J Am Heart Assoc. 2018 09 18; 7(18):e009221.
Score: 0.133
-
Long-term effects of consuming foods containing psyllium seed husk on serum lipids in subjects with hypercholesterolemia. Am J Clin Nutr. 1998 Mar; 67(3):367-76.
Score: 0.128
-
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). Am J Cardiol. 2018 04 15; 121(8):940-948.
Score: 0.127
-
A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women. Arch Intern Med. 1997 Jun 09; 157(11):1186-92.
Score: 0.122
-
Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol. 1997 Jun 01; 79(11):1475-81.
Score: 0.122
-
Efficacy of the National Cholesterol Education Program Step I diet. A randomized trial incorporating quick-service foods. Arch Intern Med. 1996 Feb 12; 156(3):305-12.
Score: 0.111
-
A psyllium-enriched cereal for the treatment of hypercholesterolemia in children: a controlled, double-blind, crossover study. Am J Clin Nutr. 1996 Jan; 63(1):96-102.
Score: 0.110
-
ETC-1002: a future option for lipid disorders? Atherosclerosis. 2014 Dec; 237(2):705-10.
Score: 0.102
-
Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy. Am J Med. 1994 Jun 06; 96(6A):37S-40S.
Score: 0.099
-
Fluvastatin Long-Term Extension Trial (FLUENT): summary of efficacy and safety. Am J Med. 1994 Jun 06; 96(6A):41S-44S.
Score: 0.099
-
Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013 Sep 24; 62(13):1154-62.
Score: 0.092
-
Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction. J Clin Lipidol. 2012 Mar-Apr; 6(2):180-91.
Score: 0.083
-
Novel developments in omega-3 fatty acid-based strategies. Curr Opin Lipidol. 2011 Dec; 22(6):437-44.
Score: 0.083
-
Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol. 2011 Sep-Oct; 5(5):338-67.
Score: 0.082
-
Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am J Cardiol. 2011 Aug 15; 108(4):523-30.
Score: 0.080
-
The hypocholesterolemic effects of beta-glucan in oatmeal and oat bran. A dose-controlled study. JAMA. 1991 Apr 10; 265(14):1833-9.
Score: 0.079
-
Focus on HDL as a therapeutic target for CAD risk reduction. Am J Cardiol. 2009 Nov 16; 104(10 Suppl):1E-2E.
Score: 0.072
-
Low high-density lipoprotein cholesterol and increased cardiovascular disease risk: an analysis of statin clinical trials. Am J Cardiol. 2009 Nov 16; 104(10 Suppl):3E-9E.
Score: 0.072
-
Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol. 2008 May 15; 101(10):1428-36.
Score: 0.065
-
Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin. 2006 Oct; 22(10):2041-53.
Score: 0.058
-
Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Rev Cardiovasc Ther. 2006 Jul; 4(4):461-76.
Score: 0.057
-
Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials. Clin Ther. 2006 Jun; 28(6):849-59.
Score: 0.057
-
A comparison of Canadian and American guidelines for lipid management using data from the National Cholesterol Education Program Evaluation ProjecT Utilizing Novel E-technology (NEPTUNE) II survey. Can J Cardiol. 2006 Mar 15; 22(4):315-22.
Score: 0.056
-
Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol. 2006 Apr 15; 97(8):1198-205.
Score: 0.056
-
Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin. J Cardiovasc Pharmacol. 2005 Nov; 46(5):594-9.
Score: 0.054
-
Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES). Circulation. 2005 Jul 26; 112(4):563-71.
Score: 0.053
-
Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia. Metabolism. 2005 Jul; 54(7):939-46.
Score: 0.053
-
Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology. 2004 Nov 23; 63(10):1902-7.
Score: 0.051
-
Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). Am Heart J. 2003 Nov; 146(5):862-9.
Score: 0.047
-
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003 Jul 15; 92(2):152-60.
Score: 0.046
-
Contemporary awareness and understanding of cholesterol as a risk factor: results of an American Heart Association national survey. Arch Intern Med. 2003 Jul 14; 163(13):1597-600.
Score: 0.046
-
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. Am J Cardiol. 2003 Mar 06; 91(5A):20C-23C; discussion 23C-24C.
Score: 0.045
-
Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group. J Clin Lipidol. 2021 Sep-Oct; 15(5):629-648.
Score: 0.041
-
Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia. Am J Cardiol. 2001 Sep 15; 88(6):635-9.
Score: 0.041
-
Lipid responses to plant-sterol-enriched reduced-fat spreads incorporated into a National Cholesterol Education Program Step I diet. Am J Clin Nutr. 2001 Jul; 74(1):33-43.
Score: 0.040
-
Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial. Am Heart J. 2001 May; 141(5):722-6.
Score: 0.040
-
Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study. J Clin Pharmacol. 2001 Jan; 41(1):70-8.
Score: 0.039
-
A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin. 2001; 17(1):43-50.
Score: 0.039
-
Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism. 2000 Sep; 49(9):1234-8.
Score: 0.038
-
Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. Am J Cardiol. 2000 Jul 15; 86(2):250-2.
Score: 0.038
-
High-molecular-weight hydroxypropylmethylcellulose taken with or between meals is hypocholesterolemic in adult men. J Nutr. 2000 Jul; 130(7):1705-10.
Score: 0.038
-
Long-term cholesterol-lowering effects of psyllium as an adjunct to diet therapy in the treatment of hypercholesterolemia. Am J Clin Nutr. 2000 Jun; 71(6):1433-8.
Score: 0.037
-
Incorporation of lean red meat into a National Cholesterol Education Program Step I diet: a long-term, randomized clinical trial in free-living persons with hypercholesterolemia. J Am Coll Nutr. 2000 Jun; 19(3):351-60.
Score: 0.037
-
Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group. Clin Cardiol. 2000 Jan; 23(1):39-46.
Score: 0.036
-
Cholesterol lowering with high-viscosity hydroxypropylmethylcellulose. Am J Cardiol. 1999 Nov 15; 84(10):1198-203.
Score: 0.036
-
Long-term blood cholesterol-lowering effects of a dietary fiber supplement. Am J Prev Med. 1999 Jul; 17(1):18-23.
Score: 0.035
-
Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group. Am J Cardiol. 1998 Aug 01; 82(3):311-6.
Score: 0.033
-
The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. Pharmacoeconomics. 1998 Jul; 14(1):59-70.
Score: 0.033
-
Cost effectiveness of treatment to National Cholesterol Education Panel (NCEP) targets with HMG-CoA reductase inhibitors. Trial design. Pharmacoeconomics. 1997 Aug; 12(2 Pt 2):278-85.
Score: 0.031
-
The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study. Clin Ther. 1996 Sep-Oct; 18(5):853-63.
Score: 0.029
-
Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995 May; 15(5):678-82.
Score: 0.026
-
The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients. Atherosclerosis. 1995 Jan 20; 112(2):223-35.
Score: 0.026
-
Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am J Cardiol. 1995 Jan 01; 75(1):34-9.
Score: 0.026
-
Effect of marine lipids on cholesteryl ester transfer and lipoprotein composition in patients with hypercholesterolemia. Arterioscler Thromb. 1992 Oct; 12(10):1146-52.
Score: 0.022
-
Effects of dietary supplementation with marine lipid concentrate on the plasma lipoprotein composition of hypercholesterolemic patients. Atherosclerosis. 1989 Oct; 79(2-3):157-66.
Score: 0.018